Squadron Capital Management’s Silence Therapeutics SLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.8M Buy
+2,085,000
New +$25.4M 5.72% 5

Other funds holding SLN

Squadron Capital Management's SLN Position: Q3 2026 in Review

Squadron Capital Management opened a new position in Silence Therapeutics (SLN) in Q3 2026: 2,085,000 shares worth $22.8M. The stake represents 5.72% of the portfolio and ranks #5 among its holdings.

92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Squadron Capital Management held 2,085,000 shares of Silence Therapeutics worth $22.8M as of Q3 2026.
  • Silence Therapeutics was a new Squadron Capital Management position in Q3 2026.
  • Silence Therapeutics made up 5.72% of Squadron Capital Management's portfolio in Q3 2026, its #5 holding.
  • 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Squadron Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.